Aardvark’s stock plummets on study pause; BioNTech heads to Phase 3 with DualityBio ADCnews2026-03-02T16:14:18+00:00March 2nd, 2026|Endpoints News|
Ginkgo divests biosecurity arm; J&J’s early prostate cancer datanews2026-02-27T15:14:31+00:00February 27th, 2026|Endpoints News|
AtaiBeckley stock drops on Phase 2a data; Disc to refile rare disease drugnews2026-02-26T16:06:55+00:00February 26th, 2026|Endpoints News|
Accent axes a cancer study; Werewolf considers its optionsnews2026-02-25T15:38:29+00:00February 25th, 2026|Endpoints News|
Beam Therapeutics’ new PKU program; Protara’s bladder cancer datanews2026-02-24T15:35:10+00:00February 24th, 2026|Endpoints News|
Merck reorganizes; Blackstone to fund trials for J&J drugnews2026-02-23T14:25:25+00:00February 23rd, 2026|Endpoints News|
Candel prices offering, signs royalty deal; Calquence label expandsnews2026-02-20T14:57:17+00:00February 20th, 2026|Endpoints News|
Biogen stops part of an MS trial; Merck reports more Enflonsia datanews2026-02-19T15:55:48+00:00February 19th, 2026|Endpoints News|
Lilly’s Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido resultsnews2026-02-18T15:16:02+00:00February 18th, 2026|Endpoints News|
Six biotechs file for HKEX listing; Faraday Pharmaceuticals shuttersnews2026-02-17T15:52:53+00:00February 17th, 2026|Endpoints News|
